Nephron sparing surgery (NSS) is considered for selected cases of upper tract urothelial carcinoma (UTUC) as it maintains renal function and avoids morbidity associated with radical nephroureterectomy (RNU). The appropriate selection of patients suitable for NSS without compromising oncological outcomes can sometimes be difficult, given the limitations of diagnostic modalities. Recurrence rates for UTUC can be as high as 36 to 54% after NSS. Intraluminal adjuvant therapy can be attempted following NSS to reduce recurrence, but delivery to the upper tract is more challenging than into the bladder. Bacillus Calmette-Guerin (BCG) and chemotherapy such as Mitomycin (MMC) have been administered via nephrostomy or ureteric catheter, which requires invasive/repeated instrumentation of the upper urinary tract. Drug delivery by reflux from bladder instillation along indwelling stents has also been tried but can potentially be unreliable. Recently, a gel formulation of mitomycin has been developed for the controlled exposure of the upper urinary tract to treatment over a number of hours. Drug-eluting stents to deliver chemotherapy to the upper urinary tract have been developed but have not yet entered clinical practice. Endoluminal phototherapy utilising an intravenous photosensitising agent is another novel approach that has recently been described. Intraluminal therapies may be beneficial in decreasing recurrence rates in UTUC, but currently have some limitations in their usage.
Objectives: To assess long‐term outcomes (up to 10 cycles) of repeated intradetrusor botulinum toxin (BoNT) utilisation in multiple sclerosis (MS) and idiopathic overactive bladder (OAB).Materials and Methods: This is a retrospective, international, multi‐centre, observational cohort study of patients diagnosed with MS and neurogenic OAB and treated with intradetrusor BoNT between January 2005 and January 2020 (just prior to COVID‐19 interruption). Dose, efficacy, duration of effect, International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ‐OAB) and International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ‐UI) measures and complication rates were recorded. Comparisons were made to those with idiopathic OAB.Results: Seven hundred and ninety‐two patients received intradetrusor BoNT treatment (104 had MS with neurogenic OAB and 688 had idiopathic OAB). Patients with MS were more likely to receive higher doses of BoNT in all cycles. Self‐reported efficacy ranged from 85.7 to 100% (MS) and 87.2 to 100% (idiopathic) with MS patients reporting increased efficacy in cycles 1–3 comparatively (p < 0.05). Duration of effect ranged from 4.5 to 9 months with a reduction in the MS cohort between cycles 1 and 10 (median 8 months vs. 5 months, p = 0.0156).Conclusion: Patients with MS and neurogenic OAB have a good therapeutic effect from intradetrusor BoNT that is sustained over at least 10 cycles with significant reduction in the duration of action with subsequent cycles.
Renal abscess is a rare manifestation of Salmonella infection. This usually occurs in the presence of risk factors that include immunosuppression, renal stones and urinary structural abnormality. We describe a 19-year-old male with no risk factors who developed a left renal abscess and gram-negative sepsis caused by Salmonella Mississippi. This was managed successfully with percutaneous drainage of the abscess and a prolonged course of antibiotics. To our knowledge, this is the first reported case of Salmonella Mississippi as a cause for renal abscess in an individual with no identifiable risk factors.
Objectives: This study aims to explore the impact of age on long‐term outcomes associated with intradetrusor botulinum toxin (BoNT) usage (up to four cycles) in elderly patients with refractory overactive bladder syndrome (OAB).Materials and Methods: We conducted a retrospective observational cohort study across institutions in Nottingham (UK) and Melbourne (Australia). Patients with refractory OAB and treated with intradetrusor BoNT between January 2005 and January 2020 were stratified into age groups: ≤40, 40–49, 50–59, 60–69 and ≥70 years. Efficacy was defined as patient self‐reported improvement in symptoms post‐BoNT injection. Duration of effect was time (months) between BoNT injection to patient reported onset of symptom recurrence. Data on BoNT type and dosing, urinary tract infection (UTI), urinary retention, ICIQ‐OAB and International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ‐UI) questionnaires were also collected. Statistical analyses were conducted with SPSS® 25 software. P‐value < 0.05 was considered statistically significant.Results: There were 943 patients stratified into age groups: < 40 (183), 40–49 (150), 50–59 (173), 60–69 (219) and ≥ 70 (218). Median age was 58 (IQR 44–69). Most patients were female 724/943 (76.8%). From Cycles 1 to 4, age group ≥ 70 efficacy rates were 85.1%, 84.1%, 92.6% and 89.3%. Corresponding median duration of effect (months) were 6.8, 8.0, 7.0 and 8.0. For Cycle 2; age ≥ 70 was a predictor of reduced efficacy (P = 0.004). Neurogenic causes of OAB were predictors of increased efficacy for Cycles 2 (P = 0.004) and 3 (P = 0.0145). Men had higher rates of urinary retention than women in Cycles 1 (42.4% vs 29.3%, P = 0.003) and 2 (37.9% vs 23.0%, P = 0.0018). All age groups showed improvement in patient‐reported outcome measures (PROMs) post‐BoNT injection.Conclusion: In elderly patients with refractory OAB and treated with intradetrusor BoNT (up to four cycles), age ≥ 70 was an independent predictor for reduced BoNT efficacy (84.1%) in Cycle 2.
We describe a unique presentation of acute lower limb ischaemia due to metastatic seminoma in a middle-aged man with a large retroperitoneal mass. The patient underwent vascular bypass surgery of the right lower limb, completed chemotherapy, and had a right scrotal orchiectomy. The patient had pre-existing vascular risk factors including peripheral vascular disease and smoking. To our knowledge this is the first published case in the literature that has described a large retroperitoneal seminoma compressing the abdominal aorta resulting in acute lower limb ischaemia.
Clinical History: We have a 70-year-old male that presented with 2 L of chronic urinary retention, lower urinary tract symptoms, prostatomegaly, and large bladder diverticulae. He initially underwent greenlight laser photovapourization of the prostate and then a second-stage robotic bladder diverticulectomy. After this second procedure, he developed perineal pain with Enterococcus faecalis demonstrated on urine culture on postoperative day 7. Physical Exam: On examination, the patient had tenderness in the pubic symphysis and perineum on palpation. He also had difficulty with mobilization. Diagnosis: A pelvis MRI confirmed a diagnosis of osteomyelitis of the pubic symphysis, with a fistula tract extending from the anterior prostate to the pubic symphysis. The patient then failed conservative urethral catheter bladder drainage and intravenous antibiotics. Intervention: Our video demonstrates the successful implementation of a robotic V-Y plasty fistula repair technique with a urachus interposition flap. Initially the prostate was separated from the pubic symphysis with endopelvic fascia dissection. The fistula tract was then identified, and the pubic bone was debrided. A V-Y plasty was performed, which closed over the fistula defect. The urachus was mobilized and brought down into the pelvis. This flap was sutured over the V-Y plasty reconstruction site. Follow-up/Outcomes: Our patient made a good postoperative recovery. He had a negative cystogram and passed a trial of void on day 14. He had a prolonged course of oral antibiotics. Follow-up CT and MRI imaging scans showed resolution of the fistula. At the 1-year follow-up, he had no further pain or lower urinary tract symptoms. Statements and Declarations: The authors have no disclosures, no acknowledgements, and no conflicts of interest. The authors declare no external funding for this study. The authors have received and archived patient consent for video/recording of surgical procedure. Runtime of video: 4 mins 45 secs.